US11992530 — Therapeutic uses for sodium thiosulfate and formulations
Method of Use · Assigned to Fennec Pharn Ceuticals Inc · Expires 2039-07-01 · 13y remaining
What this patent protects
This patent protects methods of synthesizing anhydrous sodium thiosulfate and using it to treat ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
USPTO Abstract
Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
Drugs covered by this patent
- Sodium Thiosulfate (SODIUM THIOSULFATE) · Us Army
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3948 |
— | Sodium Thiosulfate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.